ArticleBiology direct2026
Inhibition of circZFX suppresses malignant phenotypes in cholangiocarcinoma via the miR-654-3p/HDGF and YAP1 signaling activation.
Article in Biology direct, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Cholangiocarcinoma (CCA) is a highly aggressive hepatobiliary malignancy by a poor prognosis. circular RNAs (circRNAs) have poorly characterized roles in CCA. This study identified that circZFX was significantly upregulated in 4 CCA cell lines and 20 paired CCA/normal tissues. circZFX knockdown suppressed CCA proliferation, migration, and invasion in vitro and reduced xenograft tumor volume by 57% in vivo. Mechanistically, circZFX functions as a competing endogenous RNA for miR-654-3p, thus derepressing HDGF. miR-654-3p inhibitor could reverse the inhibitory effects on the proliferation activity, migration, and invasion capabilities of HuCCT1 and QBC939 cells caused by circZFX silencing. Importantly, co-immunoprecipitation revealed HDGF interaction with YAP1, and circZFX knockdown downregulated YAP1 expression. These findings indicate that inhibition of circZFX suppresses malignant phenotypes in cholangiocarcinoma via the miR-654-3p/HDGF and YAP1 signaling activation, highlighting this axis as a novel therapeutic target and providing mechanistic insights for molecular subtyping and the development of circRNA-based precision therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.